The FOXO family of Forkhead transcription factors, regulated by the phosphoinositide-3-kinase-Akt pathway, is involved in cell cycle regulation and apoptosis. Strong expression of HER2, a receptor tyrosine kinase oncogene, in cancers has been associated with a poor prognosis. Recently, FOXO4 was shown to regulate the transcription of the cyclin-dependent kinase inhibitor p27 Kip1 gene directly. Also, we have shown that HER2 promotes mitogenic growth and transformation of cancer cells by downregulation of p27 Kip1. Given the fact that FOXO4 mediates p27 transcription, we hypothesize that an Akt phosphorylation mutant of FOXO4 (FOXO4A3), which maintains the activity to transactivate p27 Kip1, may be used as an anticancer agent for HER2-overexpressing cancers. Here, we applied the FOXO4 gene as a novel anticancer agent for HER2-overexpressing cells under the control of a tetracycline (tet)-regulated gene expression system. Overexpression of FOXO4A3 inhibits HER2-activated cell growth. We found that FOXO4A3 inhibited the kinase activity of protein kinase B/Akt and reversed HER2-mediated p27 mislocation in the cytoplasm. FOXO4A3 expression also led to decreased levels of CSN5, a protein involved in p27 degradation. These data suggest that FOXO4A3 also can regulate p27 posttranscriptionally. In addition, we found that FOXO4A3 sensitized cells to apoptosis induced by the chemotherapeutic agent 2-methoxyestradiol. Most significantly for clinical application, FOXO4A3 expression in HER2-overexpressing cells can be regulated in vivo and reduces the tumor volume in a tumor model. These findings indicate the applicability of employing FOXO4 regulation as a therapeutic intervention in HER2-overexpressing cancers.
Introduction
Amplification or overexpression of the HER2/neu oncogene (also named c-erbB2 and abbreviated as HER2) is frequently found in various types of cancer, including breast, ovarian, lung, gastric, and oral cancers (Slamon et al., 1987; Hung, 1995) . Importantly, HER2 overexpression has been associated with shorter survival in cancer patients (Slamon et al., 1987) . The phosphatidylinositol 3-kinase (PI3K)-Akt signaling pathway is often deregulated in HER2-overexpressing cancer cells. HER2 can activate the Akt pathway to decrease p53 stability via mediation of MDM2 phosphorylation (Zhou et al., 2001b) . HER2 also can activate Akt to phosphorylate p21 at threonine 145, resulting in the cytoplasmic location of p21, which prevents p21's growth inhibitory activity (Zhou et al., 2001a) . We previously showed that HER2 signaling is involved in enhancing ubiquitin-mediated degradation of p27Kip1 (p27), a cyclin-dependent kinase (CDK) inhibitor, and in causing p27 cytoplasmic localization . Taken together, these data indicate that HER2 signaling deregulates negative regulators of the cell cycle, including p53, p21, and p27, thereby giving cells a mitogenic advantage.
The Forkhead FOXO transcription factor family is regulated by the PI3K-Akt pathway. This family contains three members in mammalian cells, including FOXO1 (FKHR), FOXO3a (FKHRL1), and FOXO4 (AFX). FOXO family members play important roles in cell cycle progression (Medema et al., 2000; Alvarez et al., 2001; Kops et al., 2002b) , apoptosis (Brunet et al., 1999) , oxidative stress (Kops et al., 2002a) , and DNA repair (Tran et al., 2002) . Importantly, when Akt is activated by particular extracellular signals, it can directly phosphorylate all three members of the FOXO family at three conserved serine/threonine residues (Burgering and . Phosphorylation of FOXO family member leads to its release from DNA and its subsequent retention in the cytoplasm via binding to14-3-3 protein, thereby silencing its transcriptional activity and suppressing the expression of cell cycle genes or apoptotic genes, such as the gene that encodes the p27 or the Fas ligand (reviewed in (Burgering and Tran et al., 2003) ). FOXO4 blocks G1 cell cycle progression by transcriptionally activating p27 through binding to multiple FOXO4 binding sites present in the p27 promoter (Medema et al., 2000) . p27 inhibits the activity of the CDK, thereby blocking cell cycle progression. However, it is possible that FOXO4 regulates cell cycle progression independent of p27 transcriptional activation. For example, FOXO4 still inhibits cyclin E-Cdk2 activity in p27-deficient MEF cells (Medema et al., 2000) , although to a lesser extent, suggesting the existence of a p27-independent transcriptional activation mechanism. Little is known or has been explored about these potential p27-independent mechanisms. In this report, we show that constitutively active FOXO4 (three Akt phosphorylation sites on FOXO4 (Thr32, Ser187, and Ser252) were mutated to alanine, FOXO4A3) (Medema et al., 2000) can regulate p27 post-transcriptionally.
As FOXO transcription factors are involved in cellular responses, including cell cycle, oxidative stress, and apoptosis, it is possible that deregulation of these factors leads to tumorigenesis. Given that the signal molecules involved in FOXO activity have been implicated in tumorigenesis, including PTEN (Nakamura et al., 2000), PI3K, Akt, and p27, it is not surprising that functional inactivation of FOXO results in tumorigenesis. Loss of FOXO function has been observed in rhabdomyosarcomas (Scheidler et al., 1996) , leukemias (Borkhardt et al., 1997; Corral et al., 1993) , and breast cancer (Hu et al., 2004) . In light of these important studies, it is likely that FOXO has a tumor suppressive function that is inactivated in tumorigenesis. Because of HER2's important roles in tumorigenesis, cancer cells overexpressing HER2 are an excellent target for the development of anticancer therapies. Little is known about the tumor suppressive role of FOXO4 in HER2-overexpressing cancers. Because HER2 signaling activates Akt to deregulate FOXO4 activity, enhancing FOXO4 activity may offer a therapeutic intervention in HER2-associated cancers. Here, we show that overexpressing a constitutively active FOXO4A3 in HER2-overexpressing cells suppresses cell growth. We provide experimental evidence that FOXO4A3 inhibits kinase activity of Akt and reverses HER2-mediated p27 mislocation in the cytoplasm. Also, FOXO4A3 accelerates the turnover levels of the fifth component of the COP9 signalosome (CSN) complex (CSN5, also named Jab1) (Tomoda et al., 1999; Chamovitz and Segal, 2001 ), a p27 exporter involved in p27 ubiquitination and degradation. As a result, FOXO4A3 decreases CSN5-mediated p27 ubiquitination. In addition, we found that FOXO4A3 sensitizes cells to apoptosis induced by the chemotherapeutic agent 2-methoxyestradiol (2-Me) in HER2-overexpressing cells. We then examined the effectiveness of using FOXO4A3 as a therapeutic agent for HER2-overexpressing cancer under a gene expression system regulated by tetracycline (tet) (Gossen and Bujard, 1992) . We demonstrated that the expression of FOXO4A3 can inhibit HER2-mediated cell proliferation, and anchorage-independent growth. Furthermore, we showed that FOXO4A3 expression reduces tumorigenicity of HER2-overexpressing cells in nude mice.
These results indicate that approaches for modulating FOXO4A3 activity may be useful for therapeutic intervention in HER2-overexpressing cancers.
Results

FOXO4A3 inhibits HER2-mediated mitogenic growth
HER2 signaling results in cytoplasmic localization of p27 and subsequent enhanced p27 degradation . Because FOXO4 transcriptionally activates p27, thereby blocking G1 cell cycle progression, we determined whether FOXO4 expression could reduce HER2-mediated mitogenic growth using a bromodeoxyuridine (BrdU) incorporation assay. Mink lung epithelial R1B/L17 cells were cotransfected with FOXO4 and/ or HER2-expressing plasmids and analysed by an immunofluorescence microscope for BrdU-positive cells. Whereas HER2 expression leads to increased number of BrdU-positive cells, FOXO4 or FOXO4A3, a FOXO4 with three Akt phosphorylation sites mutated to alanine, causes reduction in BrdU-positive cells as compared with the CMV empty vector transfection control cells. Importantly, cotransfection of HER2 with FOXO4 or FOXO4A3 causes a dramatic reduction in BrdUpositive cells as compared to the HER2 single-transfection cells (Figure 1a ). We chose FOXO4A3 for further study because of its efficient inhibitory effect. In addition, FOXO4A3 is not inhibited by Akt and is constitutively active. To further characterize the biological effects of FOXO4A3 expression on HER2-overexpressing cells, we employed a tet-inducible system (Gossen and Bujard, 1992) . HER2-overexpressing NIH3T3 cells stably express tTA (transcriptional activator) was established by transfecting with pUHD15-1 (neo) vector (Gossen and Bujard, 1992) . We then constructed tet-off-regulated FOXO4A3-expressing cells by transfecting pUHD10-3 hygromycin vector (Reynisdottir et al., 1995) cloned with HA-tagged FOXO4A3. We were able to identify several clones, and one representative clone can have induced expression of FOXO4A3 by adjusting the concentration of tet as detected by immunoblotting with anti-HA antibody (Figure 1b) . To assess the FOXO4A3-mediated antiproliferative effects, we measured and compared the growth inhibitory activity of FOXO4A3-expressing cell lines by measuring growth rate as determined by MTT assay (Laronga et al., 2000) and performing a BrdU incorporation assay. The FOXO4A3-expressing cells (NIH3T3/HER2/tTA-FOXO4A3 in the absence of tet) exhibited a reduced growth rate ( Figure 1c ) and a decreased BrdU-positive population (Figure 1d and e) as compared with their controls (NIH3T3/HER2/tTA-FOXO4A3 in the presence of tet).
To investigate further FOXO4A3's growth inhibitory activity, we investigated the effect of FOXO4A3 on cell cycle regulators that are regulated by HER2 or FOXO signaling, including p27 and cyclin D1 Schmidt et al., 2002) . We found that p27 protein levels were increased, whereas cyclin D1 FOXO4 inhibits tumorigenicity H Yang et al levels were diminished in the presence of FOXO4A3 expression (Figure 2a ). We also found that FOXO4A3-mediated high-level expression of p27 (Figure 2a ) inhibited CDK2-associated histone H1 kinase activity (Figure 2b ). Because cyclin D1 is a positive regulator participating in HER2 mitogenic growth (Figure 2c) , we examined the effects of FOXO4A3 on cyclin D1 expression. We found that FOXO4A3-mediated downregulation of cyclin D1 resulted from FOXO4A3's activity in antagonizing HER2-mediated cyclin D1 expression, as demonstrated by the inhibition of cyclin D1-luciferase reporter gene activation (Figure 2d ). Together, these results indicate that p27 and cyclin D1 are effectors involved in FOXO4A3-mediated cell cycle inhibition in HER2-overexpressing cells.
FOXO4A3 can affect p27 expression posttranscriptionally
p27 is known to be a direct transcriptional target of FOXO4 because p27 promoter has multiple FOXO4 binding sites (Medema et al., 2000) . We also have found that HER2 overexpression leads to p27 mislocation in the cytoplasm , which in turn facilitates the degradation of p27. In light of the observation that FOXO4A3 can induce p27 in the presence of HER2 signaling, we used immunofluorescence to determine whether the localization of p27 is affected when FOXO4A3 is induced. We found that cellular p27 is cytoplasmic in tet-treated control cells (Figure 3) , consistent with HER2's role in regulating p27 localization . Importantly, expression of FOXO4A3 induced through tet regulation led to the retention of p27 in the nucleus (Figure 3 ). These data suggest that FOXO4A3 inhibits the HER2-mediated cytoplasmic localization of p27 and may have a role in regulating p27 post-transcriptionally.
CSN5 (Jab1) is a molecule that can bind p27 and regulate the transportation of p27 into the cytoplasm for degradation (Tomoda et al., 1999) . Given that HER2 signaling leads to the cytoplasmic localization of CSN5 , which in turn may cause p27 nuclear export, we then determine whether FOXO4A3 has an 
FOXO4A3 inhibits HER2-mediated Akt activity
As Akt causes the cytoplasmic localization of some of its substrates, including p27 (Fujita et al., 2002; Shin et al., 2002) , we assayed whether FOXO4A3 impacts p27 nuclear retention in the context of HER2 overexpression by inhibiting Akt activity. We found that the phosphorylation of Akt substrates decreased ( Figure 4a ) when FOXO4A3 was induced by tet regulation in the presence of HER2 signaling. This finding suggests that FOX-O4A3 affects endogenous Akt's kinase activity toward its substrates. To further determine how the decreased phosphorylation of Akt substrates correlates with Akt activity, we determined the phosphorylation that affects Akt activation (Akt-p at Ser473) and found that S473 phosphorylation of Akt is inhibited by the expression of FOXO4A3 in cells expressing HER2. We confirmed this observation in cells transfected with constitutively active HER2 and increasing amounts of FOXO4A3: the Akt's activity toward substrates was abrogated in the presence of FOXO4A3 ( Figure 4b ). Again, we determined the phosphorylation that affects Akt activation (Akt-p at Thr308 and Akt-p at Ser473) and found that either S473 or T308 phosphorylation of Akt is inhibited by the expression of FOXO4A3 in cells expressing constitutively active HER2 ( Figure 4b ). Importantly, HER2-mediated p27 reduction was reversed with increasing amounts of FOXO4A3 ( Figure 4b ). We also have shown that the expression of PDK1, a kinase involved in T308 phosphorylation, was not altered. In addition, the expression level of PTEN, an upstream negative regulator of the PI3K-Akt pathway, did not change ( Figure 4b ). To determine whether FOXO4A3 affects the activity of Akt only in the context of constitutively active HER2, we examined the impact of FOXO4A3 toward Akt in a transfection without the constitutively active HER2 and found again that increasing amounts of FOXO4A3 inhibit the activity of Akt (Figure 5a ). In these experiments, the p27 protein level also was significantly increased following the expression of FOXO4A3. Together, these data indicate that FOXO4A3 affects the activity of Akt and causes the elevation of p27 protein.
Because increased levels of p27 concurred with decreased phosphorylation of Akt substrates (i.e., decreased Akt activity) in the presence of FOXO4A3, we inferred that FOXO4A3-mediated inhibition of Akt activity contributed to increased levels of p27.
Akt can phosphorylate GSK3b (Cross et al., 1995) . Thus, we investigated further the effects of FOXO4A3 on Akt kinase activity using a kinase assay. Cells were transfected with or without FOXO4A3. Akt was immunoprecipitated and assayed for its ability to phosphorylate GSK3b substrate. Akt-mediated phosphorylation of GSK3b was dramatically decreased in the cells transfected with FOXO4A3 (Figure 5b ). To confirm FOXO4A3's negative regulation of Akt kinase activity in a defined system, we incubated recombinant Akt, which is activated (T308D, S473D), with purified FOXO4A3 for kinase activity against purified recombinant GSK3b substrate. We found that FOXO4A3 inhibited Akt-mediated GSK3b phosphorylation (Figure 5c ).
To determine whether FOXO4A3 interacts with Akt to affect Akt's activity, we analysed the binding by coimmunoprecipitation. Cells were transfected with the expression vectors of HA-tagged FOXO4 or HA-tagged FOXO4A3, and cell lysates were immunoprecipitated with anti-HA antibody. We found that Akt is present in the anti-HA immunoprecipitation complex, suggesting that both FOXO4 and FOXO4A3 interact with Akt ( Figure 5d ). We then confirmed the binding between FOXO4A3 and Akt using a GST pull-down assay in vitro (Figure 5d ). Glutathione S-transferase (GST)-tagged FOXO4A3 was able to bind to in vitro-translated 35 S-labeled Akt (Figure 5d ), suggesting a direct binding. Taken together, these data suggest that FOXO4A3 directly interacts with Akt, and this interaction may have a role in regulating Akt negatively.
FOXO4A3 is involved in regulating CSN5 stability and activity
We showed that FOXO4A3 induction did not affect the localization of CSN5 in immunofluorescence study (Figure 3 ). We then evaluated whether FOXO4A3 had any opposing effect on CSN5 expression, which would compromise CSN5-mediated p27 degradation. Interestingly, the FOXO4A3-expressing cells (NIH3T3/HER2/ tTA-FOXO4A3 in the absence of tet) exhibited a reduced expression of CSN5 as compared with their controls (NIH3T3/HER2/tTA-FOXO4A3 in the presence of tet) (Figure 6a) . We confirmed the FOXO4A3-mediated downregulation of CSN5 in a cell transfection and also found that the expression level of CSN5 was restored when cells were treated with the specific 26S proteasome inhibitor MG132 (Figure 6b ), indicating that the downregulation of CSN5 protein by FOXO4A3 is due to the acceleration of the ubiquitin-mediated proteasome degradation of CSN5.
To further determine whether FOXO4A3-mediated low-level expression of CSN5 expression resulted from the increased degradation of CSN5, we determined the We found that the FOXO4A3-expressing cells exhibited an increased CSN5 turnover as compared with their controls (Figure 6c ). The turnover rate of CSN5 (less than 50% remained after 4 h) was faster in FOXO4A3-expressing cells than in control cells (less than 50% remained after 9 h) (Figure 6c ), suggesting that FOX-O4A3 overexpression leads to accelerated degradation of CSN5. Because CSN5 is involved in ubiquitination and degradation process of p27, we next determined whether FOXO4A3 could inhibit p27 ubiquitination even in the presence of CSN5. We cotransfected cells with pCMVFlag-p27, pCMV-CSN5, pCMV-His-ubiquitin, and increasing amounts of FOXO4A3 to perform a ubiquitination assay. Endogenous ubiquitin ligase added Hisubiquitin onto its target p27. Cells were harvested and Flag-p27 was immunoprecipitated by M2 beads, followed by immunoblotting with anti-His to observe the His-ubiquitinated form of p27. We found that the amounts of the His-ubiquitinated form of p27 decreased with increasing amounts of FOXO4A3 (compare lanes 2 and 6), suggesting that FOXO4A3 inhibits CSN5-mediated p27 ubiquitination (Figure 6e ). Taken together, these findings suggest that FOXO4A3 affects p27 stability through accelerating the degradation of CSN5, thereby decreasing CSN5-mediated p27 ubiquitination and degradation.
FOXO4A3 inhibits HER2-mediated cell survival, transformation, and tumorigenicity HER2 is implicated in processes linked to cell survival and drug resistance (Holbro et al., 2003) . Cells overexpressing HER2 may activate Akt and are more resistant to apoptosis-inducing agents such as tumor necrosis factor . Akt has been implicated in the control of cell survival. For example, mice with targeted disruption of the akt1 gene are more sensitive to apoptosis-inducing stimuli (Chen et al., 2001) . Since FOXO4A3 inhibits Akt activity, we tested whether FOXO4A3 could block the Akt-mediated survival activity in HER2-overexpressing cells. First, we determined the survival rate using an MTT assay in FOXO4A3-expressing cells (NIH3T3/HER2/tTA-FOX-O4A3 in the absence of tet) treated with 2-Me, a new anticancer agent that inhibits superoxide dismutase (SOD) and induces apoptosis in cancer cells (Huang et al., 2000) . As expected, control cells in the presence of tet did not have altered survival rates. The survival rate of FOXO4A3-expressing cells (Àtet treatment) treated with 10 mM 2-Me decreased drastically after the FOX-O4A3 induction (Figure 7a ). The survival rate was decreased to 40% after 72 h. To further confirm this observation, we measured apoptosis by quantitating DNA fragmentation using an ELISA assay to determine whether FOXO4A3 increased the efficiency of apoptosis induction by 2-Me. 2-Me alone induced marginal apoptosis at a high dose (3 mM), whereas 2-Me plus overexpression of FOXO4A3 induced through tet regulation resulted in a 1.5-3-fold increase in DNA fragmentation over that of cells treated with 2-Me only (Figure 7b ). These results indicated that FOXO4A3 promoted apoptosis and potentiated the apoptotic effects of 2-Me in HER2-overexpressing cells.
We have shown that overexpression of FOXO4A3 can inhibit cell growth in HER2-overexpressing cells. We next investigated whether FOXO4A3 overexpression affects HER2-mediated transformation. The HER2 proto-oncogene can induce transformation by enabling cells to grow in soft agar (anchorage-independent growth). Cells were treated with tet (control) or left untreated and were subjected to a soft-agar colony formation assay. Overexpression of FOXO4A3 induced through tet regulation resulted in fewer colonies than control (Figure 7c ), demonstrating that overexpression of FOXO4A3 can suppress the in vitro transformation phenotype of HER2-overexpressing cells. As FOXO4A3 blocked HER2-induced cell transformation, we next explored FOXO4A3's effect on HER2-mediated tumorigenicity in vivo. To evaluate the antitumor activity of FOXO4A3, we performed a tumorigenicity assay in immunodeficient strains of mice using doxycycline (dox, a derivative of tet) induction. Cells were treated with tet (control) or left untreated. The cells were then injected subcutaneously into the flanks of nude mice, and tumor formation was assayed. Tumor growth was observed in control mice, whereas tumor volume was dramatically decreased in mice with overexpression of FOXO4A3 induced through dox regulation (Figure 8a ). This finding suggests that FOXO4A3 inhibits HER2-mediated tumorigenicity. Tumor tissues from the sites of implantation were assessed for FOXO4A3 levels by immunoblotting. As expected, transduced HA-FOX-O4A3 protein levels were higher in mice not treated with dox (Figure 8b) , suggesting that the expression of FOXO4A3 is directly involved in inhibiting tumor growth. In addition, consistent with the results of the cell line studies, the expression of p27 also increased when FOXO4A3 was induced in the tumors (Figure 8b ). These results indicate that overexpression of FOXO4A3 is sufficient to abolish tumorigenicity in cells transformed by HER2.
Discussion
The frequent dysregulation of FOXO family in several types of cancer demonstrates that this dysregulation plays an important role in human tumorigenesis. HER2 also plays a pivotal role in cancer formation, and its oncogenic activity arises from the activation of both proliferative and antiapoptotic signaling. Akt activity is deregulated in HER2-overexpressing cancers. Given that akt signaling plays an important role in regulating FOXO family activity, the HER2-Akt-FOXO signaling pathway is an important molecular target for cancer therapy. But the tumor suppressive role of FOXO protein in HER2-overexpressing cancers remains unclear. In the study reported here, we have shown that Figure 8c) . Importantly, overexpression of FOXO4A3 inhibited tumorigenicity mediated by HER2 activity in cancer models. Given the frequent deregulation of the HER2-Akt-FOXO signaling pathway, strategic overexpression of FOX-O4A3 should prove useful in the treatment of HER2-associated tumors. In HER2-overexpressing cells, we found that induced expression of FOXO4A3 leads to increased expression of p27. FOXO4A3 is known to regulate the abundance of p27 through increased transcription, whereas it is possible that FOXO can induce the accumulation of p27 by regulating its turnover without increased transcriptional activation of p27 promoter. Zhang and Wang (2003) have observed that PAX3-FKHR fusion protein, a truncated form of FKHR, has an impact on the protein stability of p27 but no effect in transactivating the expression of p27 total mRNA. Wild-type (wt) FKHR's function in regulating the turnover of p27 has not been demonstrated yet. So far, little is known about whether FOXO4 can regulate p27 post-transcriptionally. Our results on FOXO4A3's impact on p27 upregulation can be attributed, at least in part, to post-transcriptional regulation, as demonstrated by blocking HER2-mediated p27 cytoplasmic mislocation and by inhibiting CSN5-mediated p27 ubiquitination (Figures 3 and 6) .
One particularly interesting observation is that increased expression of FOXO4A3 antagonizes HER2-mediated p27 mislocation (Figure 3 ), leading to upregulation of p27 when it antagonizes the kinase activity of Akt toward its substrates at the same time. We showed that recombinant FOXO4A3 inhibits Akt kinase activity toward GSK3 b (Figure 5 ), confirming 293T cells were cotransfected with pCMV-Flag-p27 (1 mg), pCMV-Myc-CSN5, pCMV-His-ubiquitin (1 mg), and increasing amounts of pCMV-HA-FOXO4A3 (0, 1, 4, and 8 mg). The cell lysates were harvested, and the His-ubiquitinated Flag-tagged p27 were pulled down using M2 beads (Sigma). The protein complexes were then resolved on 8% SDS-polyacrylamide gel and probed with anti-His antibody to reveal the His-ubiquitinated p27. Equal amounts of cell lysates were immunoblotted with anti-HA and anti-Myc. Lane number is indicated FOXO4 inhibits tumorigenicity H Yang et al that FOXO4A3 negatively regulates Akt. Because Akt phosphorylates p27 and causes mislocation and subsequent degradation of p27 (Fujita et al., 2002; Shin et al., 2002) , it is conceivable that FOXO4A3 may interfere with Akt-mediated p27 phosphorylation/mislocation, and in turn stabilize p27. Interestingly, a recent observation that FOXO1aD 256, a dominant-negative version of FOXO1a, can inhibit nuclear localization of p27 is further evidence that modified FOXO protein can affect the location of p27 (Cunningham et al., 2004) . It is not clear whether FOXO1aD 256 inhibits Akt kinase activity.
We found that overexpression of FOXO4A3 causes the downregulation of CSN5, which is involved in the ubiquitination and degradation of p27 (Tomoda et al., 1999) . This provides another layer of regulation for FOXO4A3-mediated p27 upregulation post-transcriptionally ( Figure 6 ). CSN5, a subunit of COP9 signalsome complex (Wei et al., 1998) , is involved in the ubiquitination and subsequent degradation of p27 (Tomoda et al., 1999) . CSN5 is abnormally expressed in several types of cancer (Kouvaraki et al., 2003; Rassidakis et al., 2003) . Little is known about how the expression of CSN5 is regulated. Our observation that FOXO4A3 accelerates the turnover rate of CSN5, thereby slowing down the CSN5-mediated p27 ubiquitination and subsequent degradation of p27 (Figure 6e) , is the first to indicate that CSN5 stability can be negatively regulated by a signal molecule. How FOX-O4A3 causes the downregulation of CSN5 remains to be characterized. It is possible that FOXO4A3 enhances the ubiquitination process of CSN5 by regulating COP9 signalsome. Another possibility is to induce the expression of ubiquitin ligase specific for CSN5 to mediate CSN5 degradation. Another report has shown that FOXO can transcriptionally activate specific ubiquitin ligase to cause muscle atrophy (Sandri et al., 2004) or to degrade HIF1a (Tang and Lasky, 2003) , suggesting that such a regulation is likely to exist. Collectively, FOXO4A3's impact on Akt activity and CSN5 stability provides evidence that FOXO4A3 can regulate p27 post-transcriptionally.
We have found that FOXO4A3 reduces the activity of Akt. We showed that FOXO4A3 directly interacts with Akt, and this interaction may regulate Akt negatively. Several mechanisms could be involved in FOXO4A3-mediated Akt inhibition: phosphorylation change in the activation loop of the catalytic domain; gene activation; or protein-protein interactions, such as carboxyl-terminal modulator protein (CTMP), a plasma membrane 
FOXO4 inhibits tumorigenicity
H Yang et al protein involved in negative regulation of Akt (Maira et al., 2001) . Obviously, FOXO4A3 inhibits Akt activity and reduces the phosphorylation of Akt on Ser473. However, we have not found that FOXO4A3 can affect the expression of 3-phosphoinositide-dependent protein kinase-1 (PDK1), a kinase involved in phosphorylation of Akt at the activation loop (Thr308) to affect the activation of Akt and subsequent phosphorylation at Ser473. Because FOXO4A3 can constitutively transactivate target genes, FOXO4A3 may regulate Akt kinase activity through inducing an Akt inhibitor such as PTEN or CTMP. However, we found that FOXO4A3 did not dramatically affect the expression of PTEN (Figure 4b ). Whether CTMP can be transcriptionally activated by FOXO4A3 remains to be investigated. As for the protein-protein interaction, FOXO4A3 may recruit CTMP to inhibit Akt kinase activity, given that CTMP also can bind and reduce the phosphorylation of Akt on Ser473 (Maira et al., 2001 (Hu et al., 2004) . Importantly, the FOXO3a mislocation is associated with a poor patient outcome (Hu et al., 2004) . It is then suggested that FOXO3a is a tumor suppressor deregulated by oncogenic signals such as Akt. Hu et al. (2004) have demonstrated that stably expressed FOXO3a can reduce the tumorigenicity of breast cancer cells MDA-MB-453 transfected with IKKb. However, the expression level of wt FOXO3a is important in tumor suppression (Hu et al., 2004) . Because wt FOXO3a is still vulnerable to Akt-or IKKb-mediated phosphorylation/degradation and subsequent deactivation in p27 induction, it is important to design a FOXO that can block negative regulation from other signal molecules. In our studies, we have shown that an Akt phosphorylation mutant version of FOXO4 (FOXO4A3) could have negative regulatory activity toward Akt and CSN5. Given that both molecules are dysregulated in cancer, we propose that FOXO4A3 has tumor suppressive activity. Indeed we have shown that FOXO4A3 inhibits the tumorigenicity of HER2-transformed cells, highlighting its tumor suppressive role. Our findings in defining the negative role of FOXO4A3 in Akt and CSN5 signaling and in exploring FOXO4A3 as an anticancer agent have important clinical relevance. Targeting Akt or CSN5 by administration of FOXO4A3 could be an excellent therapeutic regimen for the treatment of cancers in which the PI3K-Akt pathway or CSN5 pathway is constitutively activated.
Materials and methods
Cell culture and reagents
293T, NIH3T3/HER2/tTA-FOXO4A3 cells were cultured in DMEM medium containing 10% fetal bovine serum. A CaPO4 method was used to transiently transfect 293T cells. NIH3T3/HER2/tTA-FOXO4A3 cells were generated from NIH3T3/HER2/tTA cells. NIH3T3/HER2/tTA cell line was generated by transfecting pUHD15-1 (neo) vector (Gossen and Bujard, 1992) into NIH3T3/HER2 cells using the Fugene 6 transfection reagent. At 2 days after transfection, cells were selected in 600 mg/ml G418 media for 2-3 weeks. Positive clones were selected and assayed by transient transfection of pUHC13-3 (tet O/HCMVIE-luciferase) (Gossen and Bujard, 1992) .
HA-tagged FOXO4A3 DNA fragment (kind gift of Dr Burgering) was cloned into modified pUHD10-3 hygromycin vector (Reynisdottir et al., 1995) and confirmed by sequencing. The plasmid was then introduced into NIH3T3/HER2/tTA cells using Fugene 6 reagent. In all, 300 mg/ml hygromycine B plus 2 mg/ml tet were used to select for positive clones over 2-3 weeks. NIH3T3/HER2/tTA-FOXO4A3 cells were cultured in medium without 2 mg/ml tet for induced expression. Tet, 2-Me, MG132, and cycloheximide (all from Sigma) were used in the indicated experiments. Cells were treated with cycloheximide (100 mg/ml) for the indicated times to assay protein stability.
Western blot analysis
Total cell lysates were solubilized in lysis buffer (20 mM TrisHCl pH 8.0, 100 mM NaCl, 1 mM EDTA, 0.5% NP-40, 0.5% Triton X-100, 1 mM PMSF, 1 mM NaF, 1 mM sodium orthovanadate, 1 mg each of aprotinin, leupeptin, and pepstatin per ml) and were processed as previously described . For the immunoprecipitation assay, the cells were lysed and immunoprecipitated with anti-Flag (M2) (Sigma) and immunoblotted with indicated antibodies. Western blot analysis was performed on 12% polyacrylamide gels with a 5% polyacrylamide stacking gel. After electrophoretic transfer (Amersham Pharmacia) of protein from SDS-polyacrylamide gels to PVDF membranes (Millipore), the membranes were blocked with buffer containing 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween 20, 5% of blotto (Bio-Rad) for 1 h at room temperature and incubated for 1 h at room temperature with primary antibodies: anti-HA (Roche, Zymed Laboratories Inc.), anti-p27 (Zymed Laboratories Inc.), anti-PTEN (Santa Cruise), anti-PDK1 (Cell Signaling), anti-tubulin (Sigma), anti-CSN5 (GeneTex), anticyclin D1 (NeoMarkers), anti-C-neu (Ab-3, HER 2, Calbiochem), anti-HA (Upstate Biotechnology), anti-Akt (Cell Signaling), anti-phospho-(Ser/Thr) Akt substrate (Cell Signaling), and anti-phospho-Akt (Ser473) (Cell Signaling). Subsequently, membranes were washed and incubated for half an hour at room temperature with peroxidase-conjugated secondary antibodies. Following several washes, membranes were incubated with a chemiluminescence (ECL) system (Roche Molecular Biochemicals) according to the manufacturer's instructions.
Luciferase reporter gene assay
The cyclin D1-luciferase reporter (À1745CD1LUC , a gift from Dr Richard Pestell) was cotransfected with pCMV-HER2 or pCMV-FOXO4A3 expression vectors into 293T cells. Luciferase activity was assayed using the Dual Luciferase Assay system (Promega) according to the manufacturer's instructions and were processed as previously described (Zhang et al., 2004) .
Kinase assays
NIH3T3/HER2/tTA-FOXO4A3 cells were treated with or without tet. Tet-regulated or transfected cell lysates were immunoprecipitated with anti-CDK2 or anti-Akt. Immune complexes were incubated with 50 mg/ml histone H1 or 0.04 mg of GSK3b (Cell Signaling) with 10 mCi [g-32 P]ATP (Amersham) for a kinase assay as previously described (Yang et al., 2001 ). The phosphorylated substrate was visualized using a STORM840 PhosphorImager.
Ubiquitination assay
The 293T cells were cotransfected with pCMV-Flag-p27 (3 mg), pCMV-CSN5 (1 mg), His-ubiquitin (1 mg), and increasing amount of pCMV-HA-FOXO4A3. At 24 h post-transfection, cells were treated with 200 mM ALLN (MG132) (N-acetyl-LeuLeu-norleu-AL, Sigma) for 6 h. The cell lysates were harvested with lysis buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.5% NP-40, 0.5% Triton X-100, and 5 mM NEM). The His-ubiquitinated Flag-tagged p27s were pulled down using M2 beads (Sigma). The protein complexes were then resolved on 8% SDS-polyacrylamide gel and probed with anti-His to reveal the His-ubiquitinated p27.
Apoptosis assay
NIH3T3/HER2/tTA-FOXO4A3 cells were treated with 2 mg/ ml tet or without tet. Cells were then treated with apoptosisinducing agents (2-Me). Floating and attached cells were harvested 16 h after the treatment. Cells were lysed at room temperature for 30 min, and dilutions of these extracts were used for cell death ELISA, which was performed according to the manufacturer's protocol (Roche).
Immunofluorescence assay
NIH3T3/HER2/tTA-FOXO4A3 cells were treated with 2 mg/ ml tet or without tet. Cells were prepared and seeded onto chamber slides with 2 Â 10 5 cells per well 1 day prior to staining. Cells were then fixed with methanol : acetone (1 : 1 v/ v) at room temperature for 2 min and stained for 1 h with rabbit anti-p27 or anti-CSN5 (GeneTex) followed by 1 h incubation with FITC-conjugated anti-rabbit antibody (Zymed). For all staining, the cells were incubated with 0.1 mg/ml of DAPI (Sigma) to stain the nuclei. Immunofluorescence was detected using an Axioplan 2 fluorescence microscope (Zeiss).
Immunoprecipitation and in vitro binding assay 293T cell lysates from cells transfected with expressing vectors of HA-FOXO4A3 or HA-FOXO4 were immunoprecipitated with anti-HA (12CA5) and immunoblotted with anti-Akt (Cell Signaling) to detect association. The in vitro bindings assays were processed as previously described (Yang et al., 2003) . Briefly, a T7 RNA polymerase-driven vector containing the coding region of the Akt cDNA was transcribed in vitro and translated using a TNT kit (Promega). These products were labeled with [ 35 S]methionine and were then incubated with immobilized GST-FOXO4A3. The retained proteins were detected by autoradiography.
MTT assay and soft-agar colony formation assay NIH3T3/HER2/tTA-FOXO4A3 cells were treated with 2 mg/ ml tet or left untreated and were subjected to these assays. These assays were performed as described (Yang et al., 2001) .
Tumor growth in nude mice
Female 4-5-week-old nude mice (Charles River Laboratories) were maintained in the animal facility at The University of Texas MD Anderson Cancer Center. Mice were divided into two experimental groups, with six mice in each group. NIH3T3/HER2/tTA-FOXO4A3 cells (1 Â 10 6 cells in 0.2 ml PBS per injection with 2 mg/ml tet for one group, and without tet for the other) were injected subcutaneously into the flanks of mice, and each mouse was inoculated with cells at two sites. After cell inoculation, animals were fed with drinking water containing 5% sucrose in the presence or absence of 200 mg/ml dox (Sigma) (Kistner et al., 1996) . Drinking water was changed every other day for a 2-week period of tumor formation. Tumor volumes were measured and recorded every day. At the end of 2 weeks, the mice were killed, and the tumors were removed for detection of HA-FOXO4A3 and p27.
